# Phase I/II Open Label Study Evaluating the Safety and Efficacy of Combining STAT3 Inhibition (TTI-101) With Anti-PD-1 Therapy (Pembrolizumab) in Patients With Recurrent or Metastatic (RM) Head and Neck Squamous Cell Carcinoma (HNSCC)

> **NCT05668949** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **M.D. Anderson Cancer Center**

## Conditions studied

- Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** TTI-101
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT05668949
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-09-23
- **Primary completion:** 2025-09-23
- **Final completion:** 2025-09-23
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** PI requested
- **Last updated:** 2025-12-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05668949

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05668949, "Phase I/II Open Label Study Evaluating the Safety and Efficacy of Combining STAT3 Inhibition (TTI-101) With Anti-PD-1 Therapy (Pembrolizumab) in Patients With Recurrent or Metastatic (RM) Head and Neck Squamous Cell Carcinoma (HNSCC)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05668949. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*